IP Library Granted Patent US 12,345,701
Granted Patent B2
US 12,345,701 · App. 17/241,865 · Granted Jul 1, 2025

Methods for assaying biological cells in a microfluidic device

Inventors: Yelena Bronevetsky (Emeryville, CA); Annamaria Mocciaro (Emeryville, CA); Guido K. Stadler (Emeryville, CA); Peter J. Beemiller (Emeryville, CA); Natalie C. Marks (Emeryville, CA); Duane Smith (Emeryville, CA); Vincent Haw Tien Pai (Emeryville, CA); Jason M. McEwen (Emeryville, CA); Amanda L. Goodsell (Emeryville, CA); John A. Tenney (Emeryville, CA); Thomas M. Vetterli (Emeryville, CA); Hansohl E. Kim (Emeryville, CA)
Assignee: BRUKER CELLULAR ANALYSIC, INC.
G01N33/505B01L3/502761G01N33/5014B01L2200/0647
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,345,701
App. No.
17/241,865
Granted
Jul 1, 2025
Kind
B2
Abstract

Methods are provided for the assay of secreted biomolecules using automated detection and characterization of micro-objects in a microfluidic device. The biomolecules can be secreted by cells, particularly immunological cells, such as T cells. The biomolecules being assayed can include cytokines, growth factors, and the like. Methods are also provided for assaying the cytotoxicity of a cell with respect to another, target cell. Also provided are kits and non-transitory computer-readable media in which programs are stored for causing a system comprising a computer to perform automated methods for detecting secreted biomolecules and/or cytotoxicity in a microfluidic device.

Claims (40)

1. A method of assaying for antigen-specific cytotoxicity of a T lymphocyte (T cell) in a microfluidic device, the method comprising:

disposing the T cell within the microfluidic device; wherein the microfluidic device comprises a flow region for containing a flow of a first fluidic medium and a chamber opening to the flow region;

disposing a target cell in proximity to the T cell, wherein the target cell is configured to capture a secreted biomolecule from the T cell;

detecting the secreted biomolecule captured by the target cell after a period of exposure in proximity to the T cell by:

receiving a first image and one or more second images of a region of interest;

transforming each of the one or more second images to optically align with the first image;

processing pixel data in the first image using a machine learning algorithm to detect target cells present in the region of interest, the detection comprising identifying a boundary of each target cell; and

detecting a signal located within the boundary of each detected target cell in each of the one or more second images; and

determining the viability of the target cell after a period of exposure in proximity to the T cell.

2. The method of claim 1 , wherein the target cell expresses an antigen for which the T cell is specific.

3. The method of claim 1 , wherein the target cell is a cancer cell.

4. The method of claim 1 , wherein the chamber comprises a sequestration pen and the sequestration pen comprises an isolation region having a single opening and a connection region fluidically connecting the isolation region to the flow region, the isolation region being an unswept region of the microfluidic device.

5. The method of claim 1 , wherein the T cell and the target cell are each disposed in the chamber.

6. The method of claim 1 , wherein determining the viability of the target cell comprises contacting the target cell with a detectable marker configured to label a non-viable cell.

7. The method of claim 1 , further comprising labelling the T cell for the presence of one or more cell surface markers associated with proliferation, activation, metabolic activity, memory, exhaustion, and/or lineage.

8. A kit for assaying antigen-specific cytotoxicity by a T lymphocyte (T cell) in a microfluidic device, the kit comprising:

a microfluidic device comprising a flow region for containing a flow of a first fluidic medium and a chamber opening to the flow region; wherein the chamber comprises an isolation region having a single opening; and a connection region fluidically connecting the isolation region to the flow region; wherein the isolation region is an unswept region of the microfluidic device;

a cytotoxicity detection reagent configured to detect viability of a target cell; and

an image acquisition unit configured to detect a secreted biomolecule captured by the target cell when released from the T cell and:

receive a first image and one or more second images of a region of interest;

transform each of the one or more second images to optically align with the first image;

process pixel data in the first image using a machine learning algorithm to detect target cells present in the region of interest, the detection comprising identifying a boundary of each target cell; and

detect a signal located within the boundary of each detected target cell in each of the one or more second images.

9. The kit of claim 8 , wherein the cytotoxicity detection reagent comprises a reagent configured to label an apoptotic cell.

10. The kit of claim 8 , wherein the cytotoxicity detection reagent comprises a reagent configured to detect calcium flux or mitochondrial membrane potential.

11. The kit of claim 8 , further comprising a first capture object configured to capture a first secreted biomolecule of a T cell.

12. The method of claim 1 , wherein:

the first image is an illuminated image, and the second image is a non-illuminated image; or

the first image is a non-illuminated image, and the second image is an illuminated image or a non-illuminated image.

13. The method of claim 12 , wherein the non-illuminated image is a fluorescent image, an infrared image, or an ultraviolet image.

14. The method of claim 1 , wherein receiving the second image of the region of interest comprises receiving more than one second images, at least one of the more than one second images is a fluorescent image, and wherein each of the one or more second images is a fluorescent image.

15. The method of claim 13 , wherein each fluorescent image represents a fluorescent signal from a unique portion of the visible light spectrum, and wherein each fluorescent image represents fluorescent signal from a non-overlapping portion of the visible light spectrum.

16. The method of claim 1 , further comprising pre-processing the first image and the second image to reduce anomalies in the image data.

17. The method of claim 16 , wherein the pre-processing comprises reducing noise and/or optical distortion introduced during generation of the first image and the at least one second image.

18. The method of claim 1 , wherein determining a viability of the target cell further comprises processing pixel data in the first image using a machine learning algorithm and detecting the target cell present in the region of interest thereby identifying the boundary of the target cell.

19. The method of claim 18 , wherein processing pixel data in the first image comprises using the machine learning algorithm to generate a plurality of pixel masks from the first image for a corresponding plurality of target cell characteristics, and wherein each pixel mask comprises a set of pixel annotations, each pixel annotation of the set representing a probability that a corresponding pixel in the image represents the corresponding target cell characteristic.

20. The method of claim 19 , wherein the plurality of target cell characteristics comprises at least: (i) target cell center; (ii) target cell edge; and (iii) non-target cell.

21. The method of claim 20 , wherein detecting the target cell is based upon the pixel mask corresponding to the target cell center characteristic or a combination of pixel masks that includes the pixel mask corresponding to the target cell center characteristic.

22. The method of claim 1 , wherein disposing the T cell within the microfluidic device comprising disposing a single T cell into the chamber.

23. The method of claim 22 , wherein the microfluidic device further comprises a plurality of chambers and disposing the T cell within the microfluidic device comprises disposing a plurality of T cells within the microfluidic device and disposing a single T cell of the plurality of T cells into corresponding chamber of the plurality of chambers.

Assignments (3)
MERGER AND CHANGE OF NAME Recorded Nov 30, 2023
From: PHENOMEX INC.; BIRD MERGERSUB CORPORATION
To: BRUKER CELLULAR ANALYSIS, INC.
Reel/Frame 065726/0624 →
CHANGE OF NAME Recorded Sep 20, 2023
From: BERKELEY LIGHTS, INC.
To: PHENOMEX INC.
Reel/Frame 064961/0794 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2021
From: BRONEVETSKY, YELENA; MOCCIARO, ANNAMARIA; STADLER, GUIDO K.; BEEMILLER, PETER J.; MARKS, NATALIE C.; SMITH, DUANE; PAI, VINCENT HAW TIEN; MCEWEN, JASON M.; GOODSELL, AMANDA L.; TENNEY, JOHN A.; VETTERLI, THOMAS M.; KIM, HANSOHL E.
To: BERKELEY LIGHTS, INC.
Reel/Frame 056168/0395 →
Continuity (5)
Continuation PCTUS2019059495 · Nov 2, 2019
Provisional Application 62754107 · Nov 1, 2018
Provisional Application 62754147 · Nov 1, 2018
Provisional Application 62881129 · Jul 31, 2019
Related Publication 20210349075A1 · Nov 11, 2021
References Cited (110)
US 6294063B1 · Becker et al. · 2001 [cited by applicant]
US 6942776B2 · Medoro · 2005 [cited by applicant]
US 7090759B1 · Seul · 2006 [cited by applicant]
US 8581167B2 · Lean et al. · 2013 [cited by applicant]
US 9144806B2 · Chen et al. · 2015 [cited by applicant]
US 20030008364A1 · Wang et al. · 2003 [cited by applicant]
US 20040072278A1 · Chou et al. · 2004 [cited by applicant]
US 20040191789A1 · Manaresi et al. · 2004 [cited by applicant]
US 20040197905A1 · Hafeman · 2004 [cited by applicant]
US 20050112548A1 · Segawa et al. · 2005 [cited by applicant]
US 20050129581A1 · McBride et al. · 2005 [cited by applicant]
US 20050175981A1 · Voldman et al. · 2005 [cited by applicant]
US 20060091015A1 · Lau · 2006 [cited by applicant]
US 20060154361A1 · Wikswo et al. · 2006 [cited by applicant]
US 20070095669A1 · Lau et al. · 2007 [cited by applicant]
US 20070183934A1 · Diercks et al. · 2007 [cited by applicant]
US 20080223721A1 · Cohen et al. · 2008 [cited by applicant]
US 20080302732A1 · Soh et al. · 2008 [cited by applicant]
US 20090023608A1 · Hung et al. · 2009 [cited by applicant]
US 20090170186A1 · Wu et al. · 2009 [cited by applicant]
US 20100003666A1 · Lee et al. · 2010 [cited by applicant]
US 20100101960A1 · Ohta et al. · 2010 [cited by applicant]
US 20100109687A1 · Drimusz et al. · 2010 [cited by applicant]
US 20100240542A1 · Soper et al. · 2010 [cited by applicant]
US 20100273681A1 · Cerrina et al. · 2010 [cited by applicant]
US 20110053151A1 · Hansen et al. · 2011 [cited by applicant]
US 20110117634A1 · Halamish et al. · 2011 [cited by applicant]
US 20110143964A1 · Zhou et al. · 2011 [cited by applicant]
US 20110262906A1 · Dimov et al. · 2011 [cited by applicant]
US 20120009671A1 · Hansen et al. · 2012 [cited by applicant]
US 20120015347A1 · Singhal et al. · 2012 [cited by applicant]
US 20120118740A1 · Garcia et al. · 2012 [cited by applicant]
US 20120156675A1 · Lueerssen et al. · 2012 [cited by applicant]
US 20120325665A1 · Chiou et al. · 2012 [cited by applicant]
US 20130115606A1 · Hansen et al. · 2013 [cited by applicant]
US 20130118905A1 · Morimoto et al. · 2013 [cited by applicant]
US 20130121983A1 · Jones · 2013 [cited by examiner]
US 20130130232A1 · Weibel et al. · 2013 [cited by applicant]
US 20130171628A1 · Di Carlo et al. · 2013 [cited by applicant]
US 20130190212A1 · Handique et al. · 2013 [cited by applicant]
US 20130204076A1 · Han et al. · 2013 [cited by applicant]
US 20130252258A1 · Bocchi et al. · 2013 [cited by applicant]
US 20130261021A1 · Bocchi et al. · 2013 [cited by applicant]
US 20140116881A1 · Chapman et al. · 2014 [cited by applicant]
US 20140124370A1 · Short et al. · 2014 [cited by applicant]
US 20150018226A1 · Hansen et al. · 2015 [cited by applicant]
US 20150119288A1 · Soper et al. · 2015 [cited by applicant]
US 20150151298A1 · Hobbs et al. · 2015 [cited by applicant]
US 20150151307A1 · Breinlinger et al. · 2015 [cited by applicant]
US 20150165436A1 · Chapman et al. · 2015 [cited by applicant]
US 20160171686A1 · Du et al. · 2016 [cited by applicant]
US 20160184821A1 · Hobbs et al. · 2016 [cited by applicant]
US 20160193604A1 · McFarland et al. · 2016 [cited by applicant]
US 20160199837A1 · Breinlinger et al. · 2016 [cited by applicant]
US 20160252495A1 · Ricicova et al. · 2016 [cited by applicant]
US 20160312165A1 · Lowe, Jr. et al. · 2016 [cited by applicant]
US 20170224734A1 · Chapman et al. · 2017 [cited by applicant]
US 20180298318A1 · Kurz et al. · 2018 [cited by applicant]
US 20190008924A1 · Cohen · 2019 [cited by examiner]
US 20190071502A1 · Weidanz · 2019 [cited by examiner]
US 20190240665A1 · Lionberger et al. · 2019 [cited by applicant]
US 20190275516A1 · Lowe, Jr. et al. · 2019 [cited by applicant]
US 20190374944A1 · Lundquist et al. · 2019 [cited by applicant]
US 20190384963A1 · Kim et al. · 2019 [cited by applicant]
US 20200371126A1 · Thaker et al. · 2020 [cited by applicant]
US 20210272654A1 · Thaker et al. · 2021 [cited by applicant]
CN 101275114A · 2008 [cited by applicant]
CN 105492621A · 2016 [cited by applicant]
CN 108603878A · 2018 [cited by applicant]
JP 2007537729A · 2007 [cited by applicant]
KR 20100008222A · 2010 [cited by applicant]
KR 1020180091062A · 2018 [cited by applicant]
WO 2002088702A2 · 2002 [cited by applicant]
WO 2004089810A2 · 2004 [cited by applicant]
WO 2005100541A2 · 2005 [cited by applicant]
WO 2007008609A2 · 2007 [cited by applicant]
WO 2007024701A2 · 2007 [cited by applicant]
WO 2008119066A1 · 2008 [cited by applicant]
WO 2009130694A2 · 2009 [cited by applicant]
WO 2010040851A2 · 2010 [cited by applicant]
WO 2010115167A2 · 2010 [cited by applicant]
WO 2010147078A1 · 2010 [cited by applicant]
WO 2011149032A1 · 2011 [cited by applicant]
WO 2011160430A1 · 2011 [cited by applicant]
WO 2012037030A2 · 2012 [cited by applicant]
WO 2012072823A1 · 2012 [cited by applicant]
WO 2013019491A1 · 2013 [cited by applicant]
WO WO2014153651A1 · 2014 [cited by examiner]
WO 2017100347A1 · 2017 [cited by applicant]
WO 2018102748A1 · 2018 [cited by applicant]
WO 2019018801A1 · 2019 [cited by applicant]
WO 2019232473A2 · 2019 [cited by applicant]
WO 2020092975A2 · 2020 [cited by applicant]
Pietilä (Stem Cell Research & Therapy 2012 vol. 3:53). (Year: 2012). [cited by examiner]
CN108603878A, Beaumont et al.—Machine Translation, Sep. 28, 2018, 71 pages. [cited by applicant]
Chiou et al., “Massively parallel manipulation of single cells and microparticles using optical images,” Nature, vol. 436 (Jul. 21, 2005), pp. 370-372. [cited by applicant]
Chiou, Pei-Yu, Massively Parallel Optical Manipulation of Cells, Micro- and Nano-Particles on Optoelectronic devices, Dissertation, University of California at Berkeley, 2005 (147 pages). [cited by applicant]
Chung et al., Imaging Single-Cell Signaling Dynamics with a Deterministic High-Density Single-Cell Trap Array, Anal. Chem.83(18):7044-7052 (2011). [cited by applicant]
CN101275114A, Luo—Machine Translation, Oct. 1, 2008, 8 pages. [cited by applicant]
Hsu, HY et al., “Sorting of Differentiated Neurons Using Phototransistor-Based Optoelectronic Tweezers for Cell Replacement Therapy of Neurodegenerative Diseases”, Transducers 2009, Denver, CO USA Jun. 2009, download da… [cited by applicant]
Hung et al., Continuous Perfusion Microfluidic Cell Culture Array for High-Throughput Cell-Based Assays, Biotech and Bioengineering 89(1): 1-8 (2004). Dec. 3, 2004. [cited by applicant]
Iliescu et al., Continuous Field-Flow Separation of Particle Populations in a Dielectrophoretic Chip with Three Dimensional Electrodes, Applied Physics Letters 90:234104 (2007). [cited by applicant]
KIPO computer-generated English language translation of KR 20100008222A_Kyun, 2010. [cited by applicant]
Nevill et al., Integrated microfluidic cell culture and lysis on a chip, Lab on a Chip 7:1689-95 (2007). [cited by applicant]
Pavesi, A. et al. “A 3D microfluidic model for preclinical evaluation of TCR-engineered T cells against solid tumors.” JCI Insight. 2017, vol. 2, No. 12, pp. 1-18. [cited by applicant]
Somaweera H. et al., Generation of a Chemical Gradient Across an Array of 256 Cell Cultures in a Single Chip. Analyst, Oct. 7, 2013, vol. 138, No. 19, pp. 5566-5571. [cited by applicant]
Valley et al., Optoelectronic Tweezers as a Tool for Parallel Single-Cell Manipulation and Simulation, IEEE Transactions on Biomedical Circuits and Systems, vol. 3, No. 6 (Dec. 2009), pp. 424-431. [cited by applicant]
WO2010147078, University of Tokyo, Machine Translation, Dec. 23, 2010, 12 pages. [cited by applicant]
Xu, Guoling et al,. Recent Trends in Dielectrophoresis, Informacije MIDEM, 2010, vol. 40, Issue No. 4, pp. 253-262. [cited by applicant]
Yi et al., “Microfluidics technology for manipulation and analysis of biological cells,” Analytica Chimica Acta 560 (2006), pp. 1-23. [cited by applicant]